Xilio Therapeutics, Inc. (XLO)
NASDAQ: XLO · Real-Time Price · USD
0.562
+0.032 (5.96%)
Mar 9, 2026, 2:57 PM EDT - Market open
Xilio Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| TTM
| FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
| Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| Revenue | 31.8 | 6.34 | - | - | - | - | |
| Gross Profit | 26.26 | 6.34 | - | - | - | - | |
| Selling, General & Admin | 28.83 | 24.78 | 27 | 29.95 | 23.86 | 10.65 | |
| Research & Development | 41.21 | 41.21 | 52.14 | 59.2 | 51.19 | 43.91 | |
| Operating Expenses | 70.04 | 65.99 | 79.13 | 89.15 | 75.04 | 54.56 | |
| Operating Income | -43.78 | -59.65 | -79.13 | -89.15 | -75.04 | -54.56 | |
| Interest Expense | -0.1 | -0.1 | -0.7 | -0.8 | -0.6 | -0.6 | |
| Other Non Operating Income (Expenses) | -15.31 | 2.44 | 3.43 | 1.73 | -0.16 | -0.06 | |
| EBT Excluding Unusual Items | -58.49 | -57.3 | -76.4 | -88.22 | -75.8 | -55.22 | |
| Merger & Restructuring Charges | - | -0.94 | - | - | - | - | |
| Pretax Income | -58.49 | -58.24 | -76.4 | -88.22 | -75.8 | -55.22 | |
| Net Income | -58.49 | -58.24 | -76.4 | -88.22 | -75.8 | -55.22 | |
| Net Income to Common | -58.49 | -58.24 | -76.4 | -88.22 | -75.8 | -55.22 | |
| Shares Outstanding (Basic) | 52 | 54 | 27 | 27 | 6 | 1 | |
| Shares Outstanding (Diluted) | 52 | 54 | 27 | 27 | 6 | 1 | |
| Shares Change (YoY) | 17.23% | 94.62% | 0.38% | 388.59% | 970.34% | 27.97% | |
| EPS (Basic) | -1.13 | -1.09 | -2.78 | -3.22 | -13.52 | -105.42 | |
| EPS (Diluted) | -1.13 | -1.09 | -2.78 | -3.22 | -13.52 | -105.42 | |
| Free Cash Flow | -17.58 | -18.41 | -69.11 | -77.59 | -81.85 | -38.28 | |
| Free Cash Flow Per Share | -0.34 | -0.34 | -2.51 | -2.83 | -14.60 | -73.08 | |
| Gross Margin | 82.58% | 100.00% | - | - | - | - | |
| Operating Margin | -137.64% | -940.18% | - | - | - | - | |
| Profit Margin | -183.91% | -918.05% | - | - | - | - | |
| Free Cash Flow Margin | -55.28% | -290.26% | - | - | - | - | |
| EBITDA | -42.18 | -58 | -77.23 | -87.3 | -73.55 | -53.5 | |
| D&A For EBITDA | 1.59 | 1.64 | 1.9 | 1.85 | 1.5 | 1.07 | |
| EBIT | -43.78 | -59.65 | -79.13 | -89.15 | -75.04 | -54.56 | |
| Revenue as Reported | 31.8 | 6.34 | - | - | - | - | |
Source: S&P Capital IQ. Standard template.
Financial Sources.